korean semaglutide New obesity drug Mounjaro launches in Korea — is it worth switching from Wegovy? Korea weighs GLP-1 misuse label

doi: 10.3389/fbioe.2023.1279270 Received 17 August 2023 Accepted 17 October 2023 Published 30 October 2023 Volume 11 - 2023 Edited by Balaram Mohapatra, Gujarat Biotechnology Research Centre (GBRC), India Reviewed by Y

The VISTA and SOLSTICE phase 2b trials evaluated the use of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) elecoglipron in adults

From a therapeutic perspective, future efforts should focus on identifying and validating novel ferroptosis regulators, particularly those targeting non-canonical pathways

How does the MOTS-c 5-amino-1MQ stack compare to semaglutide or tirzepatide for metabolic research